[
  {
    "objectID": "shorttopic.html",
    "href": "shorttopic.html",
    "title": "Instructions for presenters in the short topic session",
    "section": "",
    "text": "What aspects have made submissions to the short topic session successful in the past?\n\nAsk one or more clear questions to panel of regulators.\nAsk questions that allow for a discussion, which do not invite a yes/no answer or an obvious answer from a regulator.\nDo your homework!\n\nHave similar questions been dealt with in other related areas, e.g. another therapeutic area or another quantitative field?\nHave regulators commented on this in other instances?\netc.\n\nReference to actual regulatory interactions, e.g. with regional differences.\nDo not ask for recipes along the lines: If we as sponsor do X will regulators then for sure agree to it?\nBefore submission of a topic ask yourself: What can a regulator meaningfully answer to my questions?\n\n\n\nFormat of the short topic session\nTo guarantee the success of the session we would like to re-iterate the format:\n\nWe have six topics distributed over two hours, which leaves each topic with 20min total time.\nYou can present for five minutes using maximum two slides.\nPresentation must be in person. There will be no virtual presentations in this session.\nPlease make sure your presentation of the issue is generic enough so that everyone in the room can follow.\nPlease ask one or more very explicit questions to the panel of regulators.\nDo not ask regulators for “recipes” in the sense of “if we do that then you guarantee to do that”.\nWhen formulating your questions ask yourself: “What would I answer if I were a regulator?” This may help to be precise and specific.\n\n\n\nDeadline\nPlease send us your slides until 21st July 2026.\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "restaurants.html",
    "href": "restaurants.html",
    "title": "Restaurants in Basel",
    "section": "",
    "text": "Name\nLink\nComment\n\n\n\n\nTibits\nWebpage\nSelf-serving, but good food and close to the station. Table booking possible as well.\n\n\nLöwenzorn\nWebpage\nThere is one that has a room for up to 25. Regarding menu, they would offer a small a-la-cart menu, so someone from the group would need to pick ahead 5 starters and 5 main dishes from the normal menu, and the group could than order on the spot from that smaller choice.\n\n\nVolkshaus\nWebpage\nSwiss and International. Price: middle.\n\n\nKohlmanns\nWebpage\nFlammenkuchen. Price: middle.\n\n\nLa Manufacture\nWebpage\nBurger. Price: middle.\n\n\nParterre\nWebpage\nSwiss and European. Price: middle.\n\n\nNoohn\nWebpage\nJapanese. Price: middle.\n\n\nRheinfelderhof\nWebpage\n\n\n\nFischerstube\nWebpage\n\n\n\nZum Braunen Mutz\nWebpage\n\n\n\nFiorentina\nWebpage\n\n\n\nKlara\nWebpage\n\n\n\nSternen\nWebpage\nPrice: a bit more expensive.\n\n\nSt. Alban Stübli\nWebpage\nPrice: a bit more expensive.\n\n\nSchützenhaus\nWebpage\nPrice: a bit more expensive.\n\n\nSafran Zunft\nWebpage\nPrice: a bit more expensive.\n\n\nAu Violon\nWebpage\nPrice: a bit more expensive. Require a fixed menu to be pre-ordered for groups.\n\n\n\n\n\nA comprehensive list of restaurants is available on the Basel webpage."
  },
  {
    "objectID": "dialin_participants.html",
    "href": "dialin_participants.html",
    "title": "Dialing-in instructions for participants",
    "section": "",
    "text": "Introduction\nYou have registered for the EFSPI regulatory statistics workshop. This document provides necessary information for virtual participants to dial in to the zoom meetings at the day of the event. For any further questions please do not hesitate to reach out to one of the local organizing committee members.\n\n\nZoom instructions\n\nEvery registered participant has received calendar invites for both days. These contain the dial-in details.\nDay 1: Use this zoom link to dial in, with passcode NA\nDay 2: Use this zoom link to dial in, with passcode NA\nDay 3: Use this zoom link to dial in, with passcode NA\nAttendees are invited to ask questions through zoom’s Q&A functionality.\nStatus of registrations: Find this here.\n\n\n\nFace-to-face attendance\n\nVenue: The event takes place in the Biozentrum in Basel (directions), in the Maurice Müller Lecture hall in the basement.\nWLAN in the Biozentrum: Connect to Unibas visitor. It will ask for your mobile phone number for confirmation.\nUpon arrival we ask you to register at the conference desk and to pick up your badge.\n\n\n\nPosting of slides and recordings\nAs soon as we get approval from speakers links to slidedecks and recordings will be posted here. This may take a few days or even weeks, depending on the responsiveness of contributors. Please do not send emails to us asking about postings. They will happen for those contributors who agree.\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "updates.html",
    "href": "updates.html",
    "title": "Updates on this page",
    "section": "",
    "text": "2024/09/30: All slidedecks for which permission for posting has been given are now available online. Recordings will follow.\n2024/06/28: Updated draft program, further speakers now confirmed.\n2024/06/10: Updated draft program, further speakers now confirmed.\n2024/06/05: Updated draft program, further speakers now confirmed.\n2024/05/31: Updated draft program, many speakers now confirmed.\n2024/05/03: Updated draft program.\n2024/04/30: Roche and Novartis again have a comprehensive block booking agreement with the workshop, see registration FAQ.\n2024/04/17: First version of draft program for 2024 workshop online.\n2024/01/29: We welcome two new members to the Scientific Committee: Welcome Bergrun Tina Magnusdottir from Iceland and Heidi Mestl from Norway!\n2024/01/10: The Scientific Committee for this year’s workshop is complete! Find the roster here."
  },
  {
    "objectID": "local.html",
    "href": "local.html",
    "title": "Local organizing Committee",
    "section": "",
    "text": "2025\nThe members of the local organizing committee in 2025 are:\n\n\n\n\n\nFirst\nLast\nType\nAffiliation\nemail\n\n\n\n\nJenny\nDevenport\nIndustry\nRoche\nJenny Devenport\n\n\nJulie\nJones\nIndustry\nNovartis\nJulie Jones\n\n\nVivian\nLanius\nIndustry\nUCB\nVivian Lanius\n\n\nHelle\nLynggaard\nIndustry\nNovo Nordisk\nHelle Lynggaard\n\n\nEgbert\nBiesheuvel\nIndustry\nViatris\nEgbert Biesheuvel\n\n\nHans Ulrich\nBurger\nIndustry\nRoche\nHans Ulrich Burger\n\n\nKaspar\nRufibach\nIndustry\nMerck KGaA\nKaspar Rufibach\n\n\nEmmanuel\nZuber\nIndustry\nNovartis\nEmmanuel Zuber\n\n\n\n\n\n\n\n2024\nThe members of the local organizing committee in 2024 were:\n\n\n\n\n\nFirst\nLast\nType\nAffiliation\n\n\n\n\nJenny\nDevenport\nIndustry\nRoche\n\n\nJulie\nJones\nIndustry\nNovartis\n\n\nHelle\nLynggaard\nIndustry\nNovo Nordisk\n\n\nEgbert\nBiesheuvel\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nIndustry\nRoche\n\n\nKaspar\nRufibach\nIndustry\nRoche\n\n\nEmmanuel\nZuber\nIndustry\nNovartis\n\n\n\n\n\n\n\n2023\nThe members of the local organizing committee in 2023 were:\n\n\n\n\n\nFirst\nLast\nType\nAffiliation\n\n\n\n\nHelle\nLynggaard\nIndustry\nNovo Nordisk\n\n\nEgbert\nBisheuvel\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nIndustry\nRoche\n\n\nChristoph\nGerlinger\nIndustry\nBayer\n\n\nKaspar\nRufibach\nIndustry\nRoche\n\n\nEmmanuel\nZuber\nIndustry\nNovartis\n\n\n\n\n\n\n\n2022\nThe members of the local organizing committee in 2022 were:\n\n\n\n\n\nFirst\nLast\nType\nAffiliation\n\n\n\n\nHelle\nLynggaard\nIndustry\nNovo Nordisk\n\n\nEgbert\nBiesheuvel\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nIndustry\nRoche\n\n\nChristoph\nGerlinger\nIndustry\nBayer\n\n\nKaspar\nRufibach\nIndustry\nRoche\n\n\nEmmanuel\nZuber\nIndustry\nNovartis\n\n\n\n\n\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "registration_faq.html",
    "href": "registration_faq.html",
    "title": "Registration for EFSPI regulatory statistics workshop: Frequently asked questions",
    "section": "",
    "text": "Introduction\nThanks for your interest in the 11th EFSPI regulatory statistics workshop! This site provides FAQs around registration.\n\n\nAre number of participants limited?\nThe biozentrum allows for 300 on-site attendees. Registration for face-to-face attendance will be stopped once we reach that number.\n\n\nIs virtual participation possible?\nYes, the workshop is hybrid.\n\n\nVenue\nThe event will take place at the Biozentrum Basel. The exact address is Spitalstrasse 41, Basel and directions are here.\nThe venue has free WLAN, just connect to Unibas visitor. It will ask for your mobile phone number for confirmation.\n\n\nProgram and registration\nProgram is not available yet.\nRegistration is not open yet.\n\n\n\n–&gt;  –&gt;      \n\n\n\nRegistration deadline\n\nFor face-to-face attendance: 4th August 2026 EOB\nRegistration platform will be turned off\n\nif we have reached maximum capacity of 300 face-to-face participants or\nfor the respective option after the deadline,\n\nwhatever happens first.\nFor virtual attendance: 17th August 2026 EOB.\n\n\nConfirmation of registration\nSome time after registration (it may take 1-2 weeks) you will receive calendar invites for the two and a half days. Please watch out for these invites, this is your confirmation of registration. If you did not receive them there is a high probability you entered your email address with a typo. If that is the case please re-register with the correct email address.\n\n\nWill the event be recorded?\nYes. Recordings will be posted here, pending speaker approval.\n\n\nWill slidedecks be shared after the event?\nYes. Slidedecks will be posted here, pending speaker approval.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMy company (NA) has a block booking for virtual participation only. I still want to attend face-to-face. How much do I need to pay?\nThe full registration fee, NA Euro.\n\n\nI will not attend the full workshop and/or not all lunches. Do I get a deducation for the face-to-face registration fee?\nNo.\n\n\nI have registered for face-to-face attendance but have changed my mind and cannot attend, not even virtually. Will my registration fee be reimbursed?\nNo. We would still very much appreciate you letting us know, for the planning of the catering.\n\n\nI have registered for face-to-face attendance but have changed my mind and will attend only virtually. Will my registration fee be reimbursed?\nNo. We would still very much appreciate you letting us know, for the planning of the catering.\n\n\nFor whom is the registration fee waived?\nSee here.\n\n\nI only want to attend parts of the workshop. Do I get a reduced fee?\nNo.\n\n\nI present a poster. Is my registration fee waived?\nNo.\n\n\nI present in the short topic session. Is my registration fee waived?\nNo.\n\n\n\n\nYou still have questions after going through this entire document?\nSend an email to Vivian Lanius."
  },
  {
    "objectID": "past.html",
    "href": "past.html",
    "title": "Past workshops",
    "section": "",
    "text": "If a recording has been made this can be found on the page with the slidedecks.\nAny views expressed in any of the slidedecks or recordings are personal and do not necessarily represent the speaker’s company or organisation’s view.\n\n\n\n\n\nYear\nProgram\nSlidedecks\n\n\n\n\n2016\nX\nX\n\n\n2017\nX\nX\n\n\n2018\nX\nX\n\n\n2019\nX\nX\n\n\n2020\nX\nX\n\n\n2021\nX\nX\n\n\n2022\nX\nX\n\n\n2023\nX\nX\n\n\n2024\nX\nX\n\n\n2025\nX\nX"
  },
  {
    "objectID": "past.html#industry",
    "href": "past.html#industry",
    "title": "Past workshops",
    "section": "Industry",
    "text": "Industry\n\n2016201720182019202020212022202320242025\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nMouna Akacha\nNovartis\n\n\nKaspar Rufibach\nRoche\n\n\nHans Ulrich Burger\nRoche\n\n\nChrissie Fletcher\nAmgen\n\n\nChristoph Gerlinger\nBayer\n\n\nMichael Kunz\nBayer\n\n\nKristina Weber\nRoche\n\n\nThomas Dumortier\nNovartis\n\n\nSteffen Ballerstedt\nNovartis\n\n\nGeorge Quartey\nRoche\n\n\nAlexander Schacht\nLilly\n\n\nJens Lamerz\nRoche\n\n\nBruno Boulanger\nArle\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nFrank Bretz\nNovartis\n\n\nFrancesca Callegari\nNovartis\n\n\nKaspar Rufibach\nRoche\n\n\nChrissie Fletcher\nAmgen\n\n\nRichardus Vonk\nBayer\n\n\nOliver Sander\nNovartis\n\n\nAchim Guettner\nNovartis\n\n\nAndy Stone\nStone biostatistics\n\n\nAllison Florance\nNovartis\n\n\nDominik Heinzmann\nRoche\n\n\nHans Ulrich Burger\nRoche\n\n\nViktoriya Stalbovskaya\nNovartis\n\n\nAmy Racine\nNovartis\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nChrissie Fletcher\nAmgen\n\n\nNicolas Rouyrre\nNovartis\n\n\nNikolaos Sfikas\nNovartis\n\n\nFabian Model\nRoche\n\n\nKapildeb Sen\nNovartis\n\n\nDavid Kardatzke\nRoche\n\n\nHans Ulrich Burger\nRoche\n\n\nJiawei Wei\nNovartis\n\n\nFranco Mendolia\nBayer\n\n\nTobias Mütze\nNovartis\n\n\nCarol Reid\nRoche\n\n\nSebastian Weber\nNovartis\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nSimon Wandel\nNovartis\n\n\nFabian Model\nRoche\n\n\nHendrik Schmidt\nBoehringer-Ingelheim\n\n\nKate Taylor\nAmgen\n\n\nStanislas Hubeaux\nRoche\n\n\nChristoph Gerlinger\nBayer\n\n\nGian Thanei\nRoche\n\n\nSteffen Falgreen Larsen\nNovo Nordisk\n\n\nHans Ulrich Burger\nRoche\n\n\nGeorg Kralidis\nGruenenthal\n\n\nMarcel Wolbers\nRoche\n\n\nEvgeny Degtyarev\nNovartis\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nJanet Wittes\nStatistics Collaborative Inc.\n\n\nPaul Gallo\nNovartis\n\n\nLisa Squassante\nRoche\n\n\nHans Ulrich Burger\nRoche\n\n\nVivian Lanius\nBayer\n\n\nArmin Schüler\nMerck KGaA\n\n\nDavid Wright\nAstraZeneca\n\n\nYongming Gu\nEli Lilly\n\n\nGuenther Mueller-Velten\nNovartis\n\n\nYi Wang\nNovartis\n\n\nMelanie Wright\nNovartis\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nDon Berry\nBerry Consultants\n\n\nJames Bell\nElderbrook Solutions\n\n\nMagalie Hilton\nRoche\n\n\nEgbert Biesheuvel\nDanone\n\n\nMichael O’Kelly\nIQVIA\n\n\nJiawen Zhu\nRoche\n\n\nAlexandra Vaury\nNovartis\n\n\nPhilip Hougaard\nLundbeck\n\n\nChristoph Gerlinger\nBayer\n\n\nQing Wang\nRoche\n\n\nMarianne Cunnington\nGSK\n\n\nAnny Stari\nPSI / EFSPI RWD SIG chair\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nFrank Bretz\nNovartis\n\n\nMouna Akacha\nNovartis\n\n\nBjörn Bornkamp\nNovartis\n\n\nKaspar Rufibach\nRoche\n\n\nSteve Ruberg\nAnalytix thinking\n\n\nDieter Haering\nNovartis\n\n\nMarius Thomas\nNovartis\n\n\nStephen Senn\nStatistical Consultant\n\n\nJoshua Ray\nRoche\n\n\nRob Hemmings\nConsilium\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nDieter Haering\nNovartis\n\n\nDavid Wright\nAstraZeneca\n\n\nCourtney Schiffman\nRoche\n\n\nEmmanuel Zuber\nNovartis\n\n\nFrank Bretz\nNovartis\n\n\nHans Ulrich Burger\nRoche\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nKaspar Rufibach\nBetween jobs\n\n\nEmmanuel Zuber\nConsultant\n\n\nJenny Devenport\nRoche\n\n\nFredrik Öhrn\nJohnson and Johnson\n\n\nJulie Jones\nNovartis\n\n\nVivian Lanius\nBayer\n\n\nBrett Hauber\nPfizer\n\n\nKatrin Kupas\nBMS\n\n\nJohan Hellsten\nLundbeck\n\n\nFrank Bretz\nNovartis\n\n\nLara Wolfson\nMSD\n\n\nAntonio Remiro-Azocar\nNovo Nordisk\n\n\nSandro Gsteiger\nRoche\n\n\nAlessandro Gasparini\nConsultant\n\n\nRob Hemmings\nConsultant\n\n\nLilla Di Scala\nJohnson and Johnson\n\n\nMouna Akacha\nNovartis\n\n\nJuha-Pekka Perttola\nRoche\n\n\nPierre Mancini\nSanofi\n\n\nPeter Ahnesorg\nRoche\n\n\nGiulia Zigon\nGSK\n\n\nSteffen Falgreen Larsen\nNovo Nordisk\n\n\nKarin Cerri\nJohnson and Johnson\n\n\nXiaoni Liu\nNovartis\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nAntonio Remiro-Azócar\nNovo Nordisk\n\n\nChris Harbron\nRoche\n\n\nClaudia Dallinger\nBoehringer Ingelheim\n\n\nEgbert Biesheuvel\nViatris\n\n\nEmmanuel Zuber\nCogitamen\n\n\nFrank Bretz\nNovartis\n\n\nFredrik Öhrn\nJ&J\n\n\nHenrik F. Thomsen\nNovo Nordisk\n\n\nJenny Devenport\nRoche\n\n\nJulie Jones\nNovartis\n\n\nJürgen Hummel\nNovo Nordisk\n\n\nKaspar Rufibach\nMerck\n\n\nMickaël De Backer\nUCB\n\n\nMouna Akacha\nNovartis\n\n\nNicky Best\nGSK\n\n\nOliver Sailer\nBoehringer Ingelheim\n\n\nPatrick Schloemer\nBayer\n\n\nPierre Mancini\nSanofi\n\n\nRima Izem\nNovartis\n\n\nSimon Wandel\nNovartis\n\n\nThomas Hiemstra\nNovartis\n\n\nTobias Mielke\nJ&J\n\n\nValerie Nock\nBoehringer Ingelheim\n\n\nSilke Jörgens\nJ&J"
  },
  {
    "objectID": "past.html#european-regulator",
    "href": "past.html#european-regulator",
    "title": "Past workshops",
    "section": "European Regulator",
    "text": "European Regulator\n\n2016201720182019202020212022202320242025\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nFrank Pétavy\nEuropean Regulator\n\n\nNorbert Benda\nBfArM\n\n\nAnn-Kristin Leuchs\nBfArM\n\n\nThomas Lang\nAGES\n\n\nArmin Koch\nHannover Medical School\n\n\nJacob Brogren\nMedical Products Agency Sweden\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nFrank Pétavy\nEMA\n\n\nLorenzo Guizzaro\nEMA\n\n\nArmin Koch\nHannover Medical School\n\n\nNorbert Benda\nBfArM\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nFrank Pétavy\nEMA\n\n\nAnja Schiel\nNorwegian Medicines Agency\n\n\nAndreas Brandt\nBfArM\n\n\nBenjamin Hofner\nPaul-Ehrlich Institute\n\n\nFlora Musuamba Tshinanu\nBelgian Federal Agency for Medicines and Health Products\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nLorenzo Guizzaro\nEMA\n\n\nKit Roes\nRadboud University Medical Center\n\n\nBenjam Hofner\nPaul-Ehrlich Institute\n\n\nHilke Zander\nPaul-Ehrlich Institute\n\n\nLukas Aguirre Davila\nHannover Medical School\n\n\nCharlotte Gaasterland\nKnowledge Institute of the Federation of Medical Specialists, Netherlands\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nSteven Teerenstra\nRadboud University Medical Center\n\n\nFinbarr Leacy\nHealth Products Regulatory Authority, Ireland\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nPeter Arlett\nEMA\n\n\nRalf Herold\nEMA\n\n\nAnja Schiel\nNorwegian Medicines Agency\n\n\nArmin Koch\nHannover Medical School\n\n\nKit Roes\nRadboud University Medical Center\n\n\nChantal Quinten\nEMA\n\n\nCorinne de Vries\nEMA\n\n\nElina Asikanius\nFinnish Medicines Agency\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nEftychia-Eirini Psarelli\nEMA\n\n\nAnja Schiel\nNorwegian Medicines Agency\n\n\nKit Roes\nRadboud University Medical Center\n\n\nTheodor Framke\nHannover Medical School\n\n\nArmin Koch\nHannover Medical School\n\n\nAndreas Brandt\nBfArM\n\n\nFlorian Klinglmüller\nAGES\n\n\nAnders Viberg\nDental and Pharmaceutical Benefits Agency, Sweden\n\n\nKatharina Hees\nPaul-Ehrlich Institute\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nKristin Karlsson\nSwedish Medical Products Agency\n\n\nEftychia-Eirini Psarelli\nEMA\n\n\nWolfgang Jacquet\nVrije Universiteit Brussel\n\n\nBenjamin Hofner\nPaul-Ehrlich Institute\n\n\nTommi Nurminen\nFinnish Medicines Agency\n\n\nAntero Kallio\nFinnish Medicines Agency\n\n\nKit Roes\nRadboud University Medical Center\n\n\nAndreas Brandt\nBfArM\n\n\nElina Asikanius\nFinnish Medicines Agency\n\n\nLukas Aguirre Dávila\nPaul-Ehrlich Institute\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nBergrún Magnúsdóttir\nRegulator Europe (EMA)\n\n\nFlorian Lasch\nRegulator Europe (EMA)\n\n\nLaura Rodwell\nRegulator Netherlands (CBG-MEB)\n\n\nBenjamin Hofner\nRegulator Germany (PEI / BfARM / BVL)\n\n\nSarianne Paeivike\nRegulator Finland (FIMEA)\n\n\nElina Asikanius\nRegulator Finland (FIMEA)\n\n\nHeidi Mestl\nRegulator Norway (NOMA)\n\n\nAndreas Brandt\nRegulator Germany (PEI / BfARM / BVL)\n\n\nLukas Aguirre Davila\nRegulator Germany (PEI / BfARM / BVL)\n\n\nTobias Fellinger\nRegulator Austria (AGES)\n\n\nFlorian Klinglmueller\nRegulator Austria (AGES)\n\n\nAysun Cetinyurek Yavuz\nRegulator Netherlands (CBG-MEB)\n\n\nKit Roes\nRadboud MC\n\n\nFrancesco Pignatti\nRegulator Europe (EMA)\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nAndreas Brandt\nBfARM\n\n\nAngelika Geroldinger\nRegulator Austria (AGES)\n\n\nAysun Cetinyurek Yavuz\nRegulator Netherlands (CBG-MEB)\n\n\nBergrún Tinna Magnúsdottir\nIMA\n\n\nElina Asikanius\nfimea\n\n\nFlorian Krach\nPEI\n\n\nFlorian Klinglmueller\nRegulator Austria (AGES)\n\n\nFlorian Lasch\nEMA\n\n\nFrank Pétavy\nEMA\n\n\nGabriel Westman\nMPA\n\n\nHeidi Mestl\nNOMA\n\n\nKatharina Hees-Krumm\nPEI\n\n\nKhadija Rantell\nMHRA\n\n\nLukas Aguirre Dávila\nPEI\n\n\nMaria Grünewald\nMPA\n\n\nRafael Sauter\nSwissmedic\n\n\nTommi Nurminen\nfimea\n\n\nXiaofei Liu\nBfARM\n\n\nFlora Musuamba Tshinanu\nUniversity of Namur\n\n\nKit Roes\nRadboud UMC"
  },
  {
    "objectID": "past.html#mhra",
    "href": "past.html#mhra",
    "title": "Past workshops",
    "section": "MHRA",
    "text": "MHRA\n\n201620172018201920212022202320242025\n\n\n\n\n\n\n\nName\n\n\n\n\nDavid Wright\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nKhadija Rantell\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nRob Hemmings\n\n\nKhadija Rantell\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nKhadija Rantell\n\n\nJohn Johnston\n\n\nInes Reis\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nKhadija Rantell\n\n\nKirsty Wydenbach\n\n\nTim Williams\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nJasvinder Singh\n\n\nKhadija Rantell\n\n\nJohn Johnston\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nKhadija Rantell\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nJohn Johnston\n\n\nKhadija Rantell\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nAndrea Manfrin"
  },
  {
    "objectID": "past.html#fda",
    "href": "past.html#fda",
    "title": "Past workshops",
    "section": "FDA",
    "text": "FDA\n\n2016201720182021202220232024\n\n\n\n\n\n\n\nName\n\n\n\n\nThomas Permutt\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nJohn Scott\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nRajeshwari Sridhara\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nMark Levenson\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nAloka Chakravarty\n\n\nRajeshwari Sridhara\n\n\nWanje Sun\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nDaniel Rubin\n\n\nPallavi Mishra-Kalyani\n\n\nMark Levenson\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nPaul Schuette\n\n\nGregory Levin\n\n\nMiya Paterniti"
  },
  {
    "objectID": "past.html#pmda-japan",
    "href": "past.html#pmda-japan",
    "title": "Past workshops",
    "section": "PMDA Japan",
    "text": "PMDA Japan\n\n20212022\n\n\n\n\n\n\n\nName\n\n\n\n\nYuki Ando\n\n\n\n\n\n\n\n\n\n\n\n\nName\n\n\n\n\nYuki Ando"
  },
  {
    "objectID": "past.html#hta",
    "href": "past.html#hta",
    "title": "Past workshops",
    "section": "HTA",
    "text": "HTA\n\n201820212022202320242025\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nAnja Schiel\nNorwegian Medicines Agency\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nAnja Schiel\nNorwegian Medicines Agency\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nAnja Schiel\nNorwegian Medicines Agency\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nDavid McConnell\nStatistician National Centre for Pharmacoeconomics, Ireland\n\n\nGergő Merész\nNational Centre for Public Health and Pharmacy, Hungary\n\n\nStefan Lange\nIQWiG\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nWim Goettsch\nUMC Utrecht\n\n\nDavid Mcconnell\nNCPE, EU HTACG Methodology Subgroup\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nAnja Schiel\nNOMA\n\n\nSeamus Kent\nESHPM"
  },
  {
    "objectID": "past.html#academia",
    "href": "past.html#academia",
    "title": "Past workshops",
    "section": "Academia",
    "text": "Academia\n\n20162018201920202021202220242025\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nTim Friede\nUni Goettingen\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nJames Roger\nLondon School of Hygiene and Tropical Medicine\n\n\nChristian Röver\nUni Göttingen\n\n\nTim Friede\nUni Göttingen\n\n\nSarah Zohar\nINSERM, Paris\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nStephen Evans\nLondon School of Hygiene and Tropical Medicine\n\n\nTim Friede\nUniversity of Goettingen, on behalf of SAVVY working group\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nThomas Jaki\nMRC Cambridge Biostatistics Unit\n\n\nTom Fleming\nUniversity of Washington\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nMira Zuidgeest\nUMC Utrecht\n\n\nDipak Kotecha\nUni Birmingham\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nMats Stensrud\nEPFL Lausanne\n\n\nFabrizia Mealli\nUni Florence\n\n\nFranz Koenig\nUni Vienna\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nYan Hou\nPeking University\n\n\n\n\n\n\n\n\n\n\n\n\nName\nAffiliation\n\n\n\n\nChristopher Jennison\nUniversity of Bath\n\n\nMiguel Hernán\nHavard university\n\n\nNorbert Benda\nUniversity of Göttingen\n\n\nOlaf Klungel\nUniversity of Utrecht\n\n\nTim Friede\nUniversity of Göttingen\n\n\nHans Ulrich Burger\nMedical University of Graz"
  },
  {
    "objectID": "feedback.html",
    "href": "feedback.html",
    "title": "EFSPI regulatory statistics workshop: feedback from previous years",
    "section": "",
    "text": "Feedbacks from previous years (on purpose not linked on main site)\n\n\n\n\n\nYear\nFeedbacks\n\n\n\n\n2016\n\n\n\n2017\n\n\n\n2018\n\n\n\n2019\n2019\n\n\n2020\n2020\n\n\n2021\n2021\n\n\n2022\n2022\n\n\n2023\n2023\n\n\n2024\n\n\n\n2025\n\n\n\n2026\n\n\n\n\n\n\n\n\nWho to provide feedback to\nFor feedback on this page send an email to Kaspar Rufibach."
  },
  {
    "objectID": "data/2026/slides.html",
    "href": "data/2026/slides.html",
    "title": "EFSPI regulatory statistics workshop",
    "section": "",
    "text": "Will be added after the 2026 workshop."
  },
  {
    "objectID": "data/2025/analysis2025.html",
    "href": "data/2025/analysis2025.html",
    "title": "EFSPI regulatory statistics workshop 2025: analysis of registrations",
    "section": "",
    "text": "Data status\nData as of 2025-10-07 at 19:46:33.\n\n\nRegistrations\n\nBy type of institutionBy backgroundBy institutionRegulatory colleaguesHTA colleaguesBy countriesBy countries - mapBy geographic regionBy mode of attendance\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nRegistration waived yes / no\n\n\n\n\n\n\n\n\n\n\n\nAnalysis of block booking\n\nRegistrations of members of companies with F2F block bookingRegistrations of members of companies with virtual block booking\n\n\nPre-booked numbers are:\n\n\n\n\nCompany\nRoche\nNovartis\nBoehringer Ingelheim\n\n\nPre-booked F2F seats\n50\n50\n30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBoehringer Ingelheim (N=27)\nNovartis (N=107)\nRoche (N=62)\nTotal (N=196)\n\n\n\n\nmode\n\n\n\n\n\n\n   Face-to-face (280 Euro)\n20 (74.1%)\n51 (47.7%)\n49 (79.0%)\n120 (61.2%)\n\n\n   Virtual (70 Euro)\n7 (25.9%)\n56 (52.3%)\n13 (21.0%)\n76 (38.8%)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBayer (N=79)\nBMS (N=83)\nMerck KGaA (N=60)\nTotal (N=222)\n\n\n\n\nmode\n\n\n\n\n\n\n   Face-to-face (280 Euro)\n13 (16.5%)\n5 (6.0%)\n2 (3.3%)\n20 (9.0%)\n\n\n   Virtual (70 Euro)\n66 (83.5%)\n78 (94.0%)\n58 (96.7%)\n202 (91.0%)\n\n\n\n\n\n\n\n\nAnalysis of face-to-face attendance and catering\nThe room at Biozentrum has about 300 seats.\n\nNumber of F2F spaces already bookedMeals and wine tasting for those registered for face-to-face attendanceMeals and wine tasting for those registered for face-to-face attendance, Novartis and Roche onlyMeals and wine tasting for those registered for face-to-face attendance, all except Novartis and Roche\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo shows\nAnalysis will be provided after the event.\n\n\nNo-shows among those who registered for face-to-face participation\n\n\n\n\n\n\n\n\n\n\nNovartis (N=51)\nRoche (N=49)\nTotal (N=100)\n\n\n\n\nnoshow\n\n\n\n\n\n   show\n51 (100.0%)\n41 (83.7%)\n92 (92.0%)\n\n\n   no show\n0 (0.0%)\n8 (16.3%)\n8 (8.0%)"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "EFSPI regulatory statistics workshop",
    "section": "",
    "text": "EFSPI regulatory statistics workshop\nEach year, a small team of volunteers organizes the EFSPI Regulatory Statistics Workshop on behalf of EFSPI. The goal of the workshop is to bring together statisticians and partner functions from pharmaceutical industry, regulatory agencies, and academia to discuss topics of common interest.\nThe unique feature of the workshop is an atmosphere of collaboration and open discussion of statistical and regulatory science in general. Over the years the workshop has sharpened its profile and with regular participation of speakers from regulatory agencies such as EMA, many European regulatory agencies, FDA, PMDA, MHRA, and many more has become a voice in the global dialogue on regulatory statistics. Furthermore, with HTA considerations becoming ever more important in Europe and beyond topics pertinent to HTA are also increasingly discussed.\nSince its inception in 2016 the workshop has always taken place in Basel, Switzerland. Details about the 2026 issue are available here.\n\n\nParallel workshop in the US\nThe ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop is organized by the ASA and FDA.\nBoth these workshops aspire to build a statistical community across regulatory agencies and industry. Both events provide a forum to discuss topics of common interest for industry and regulators and offer many opportunities for everyone to participate in these discussions and impact alignment.\n2025 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\nWhat you find here\nOn this webpage you find links and materials for the yearly EFSPI regulatory statistics workshop in Basel.\nThe workshop is organized by EFSPI.\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "testimonials2022.html",
    "href": "testimonials2022.html",
    "title": "Testimonials from 2022 workshop",
    "section": "",
    "text": "Name\nFunction\nLink to video\n\n\n\n\nGeneral promotion video\n\nvideo\n\n\nSteve Ruberg\nlegendary pharma statistician and consultant\nvideo\n\n\nCharis Papavassilis\nGlobal Head Early Portfolio for dermatology, autoimmunity, and skeletal diseases\nvideo\n\n\nNovartis voices\n\nvideo\n\n\n\n\n\nSlidedeck with Summary and feedback.\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "data/2025/slides.html",
    "href": "data/2025/slides.html",
    "title": "Recordings",
    "section": "",
    "text": "Slidedecks and recordings will be continuously added as soon as we have them and the presenter’s consent.\nDownload all materials as .zip file"
  },
  {
    "objectID": "data/2025/slides.html#session-1-overture-strategic-priorities-in-pharmaceutical-statistics",
    "href": "data/2025/slides.html#session-1-overture-strategic-priorities-in-pharmaceutical-statistics",
    "title": "Recordings",
    "section": "Session 1: Overture: Strategic Priorities in Pharmaceutical Statistics",
    "text": "Session 1: Overture: Strategic Priorities in Pharmaceutical Statistics\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nKit Roes (Chair of MWP EMA, Radboud UMC, NL)\nNavigating priorities from regulatory perspective\nx\n\n\n2\nMouna Akacha (Co-chair EFSPI statistical methodology leaders, Novartis, CH)\nStrategic priorities in pharmaceutical statistics – A quantitative drug developer’s perspective\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-2-ich-e20-guideline-on-adaptive-designs-for-clinical-trials-a-critical-discussion-from-different-perspectives",
    "href": "data/2025/slides.html#session-2-ich-e20-guideline-on-adaptive-designs-for-clinical-trials-a-critical-discussion-from-different-perspectives",
    "title": "Recordings",
    "section": "Session 2: ICH E20 Guideline on Adaptive Designs for Clinical Trials – A Critical Discussion from Different Perspectives",
    "text": "Session 2: ICH E20 Guideline on Adaptive Designs for Clinical Trials – A Critical Discussion from Different Perspectives\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nFrank Pétavy (EMA, NL), Khadija Rantell (MHRA, UK)\nMoving towards harmonisation for (confirmatory) trials with an adaptive design\nx\n\n\n2\nChristopher Jennison (University of Bath, UK)\nICH E20 guideline on adaptive designs for clinical trials: my reflections as a statistician working in Academia\nx\n\n\n3\nSilke Jörgens (J&J/University of Cologne, DE)\nICH E20 guideline on adaptive designs for clinical trials: my reflections as a statistician working in Industry\nx\n\n\n4\nMaria Grünewald (MWP member, MPA, SE)\nICH E20 guideline on adaptive designs for clinical trials: my reflections as a statistician working in Regulatory assessment\nx\n\n\n5\nSeamus Kent (ESHPM, NL)\nICH E20 guideline on adaptive designs for clinical trials: my reflections as a statistician working in HTA assessment\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-3-anniversary-session",
    "href": "data/2025/slides.html#session-3-anniversary-session",
    "title": "Recordings",
    "section": "Session 3: Anniversary session",
    "text": "Session 3: Anniversary session\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nEmmanuel Zuber (cogitamen, CH), Hans Ulrich Burger (Medical University of Graz, DE), Egbert Biesheuvel (Viatris, NL)\n10th EFSPI regulatory statistics workshop\nx\n\n\n2\nJulie Jones (Novartis), Andreas Brandt (BfARM), Elina Asikanius (fimea), Jenny Devenport (Roche)\nTackling the Hard Topics: Shaping What’s Next in Regulatory Science\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-4-from-trials-to-target-populations-extending-evidence-for-decision-making",
    "href": "data/2025/slides.html#session-4-from-trials-to-target-populations-extending-evidence-for-decision-making",
    "title": "Recordings",
    "section": "Session 4: From Trials to Target Populations: Extending Evidence for Decision-Making",
    "text": "Session 4: From Trials to Target Populations: Extending Evidence for Decision-Making\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nSeamus Kent (ESHPM, NL)\nIntro\nx\n\n\n2\nAntonio Remiro-Azócar (Novo Nordisk, ES)\nEvidence synthesis: estimands, transportability and external validity\nx\n\n\n3\nMiguel Hernán (Harvard T.H. Chan School of Public Health, US)\nEmulation of target trials using observational data: because randomized trials cannot possibly answer all causal questions\nx"
  },
  {
    "objectID": "data/2025/slides.html#short-topics-present-a-problem-on-2-3-slides-and-receive-input-from-a-panel-of-regulators",
    "href": "data/2025/slides.html#short-topics-present-a-problem-on-2-3-slides-and-receive-input-from-a-panel-of-regulators",
    "title": "Recordings",
    "section": "Short topics: Present a problem on 2-3 slides and receive input from a panel of regulators",
    "text": "Short topics: Present a problem on 2-3 slides and receive input from a panel of regulators\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nGaelle Klingelschmitt, Jianmei Wang, Audrey Boruvka, Jenny Devenport (Roche, CH / UK / CA)\nSurprises matter! Limiting broad disclosure of futility analysis criteria to preserve trial integrity\nx\n\n\n2\nRob Hemmings (Consilium, UK)\nAccessing accumulating data in open-label studies\nx\n\n\n3\nFranco Mendolia, Katja Brandau (Bayer, DE)\nThe future of per protocol set analyses in non-inferiority trials\nx\n\n\n4\nThomas Hoefelder, Beate Presser (Boehringer Ingelheim, DE)\nHow can we strengthen statisticians’ impact in CMC related ICH guidelines? - Special focus on ICH M13b concerning dissolution profiles\nx\n\n\n5\nBohdana Ratitch, Alfredo Farjat (Bayer, CA/NL)\nAcceptability of prognostic covariate adjustment and Targeted Maximum Likelihood Estimation (TMLE) methods for the primary and key analyses of pivotal clinical trials in absence of prior clinical knowledge about strong predictive factors\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-5-from-black-box-to-pandoras-box-navigating-ai-in-clinical-trials",
    "href": "data/2025/slides.html#session-5-from-black-box-to-pandoras-box-navigating-ai-in-clinical-trials",
    "title": "Recordings",
    "section": "Session 5: From Black Box to Pandora’s Box: Navigating AI in Clinical Trials",
    "text": "Session 5: From Black Box to Pandora’s Box: Navigating AI in Clinical Trials\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nTim Friede (University of Göttingen, DE)\nAI in clinical trials: Is there a role for statistics?\nx\n\n\n2\nGabriel Westman (MWP member, MPA, SE)\nAI in clinical trials – a regulatory perspective\nx\n\n\n3\nChris Harbron (Roche, UK)\nWill industry need statisticians in an AI world?\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-6-characterizing-the-effect-of-treatment-using-hierarchical-composite-endpoints-risks-and-benefits-of-win-statistics-and-beyond",
    "href": "data/2025/slides.html#session-6-characterizing-the-effect-of-treatment-using-hierarchical-composite-endpoints-risks-and-benefits-of-win-statistics-and-beyond",
    "title": "Recordings",
    "section": "Session 6: Characterizing the Effect of Treatment Using Hierarchical Composite Endpoints – Risks and Benefits of Win Statistics and Beyond",
    "text": "Session 6: Characterizing the Effect of Treatment Using Hierarchical Composite Endpoints – Risks and Benefits of Win Statistics and Beyond\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nHenrik F. Thomsen (Novo Nordisk, DK), Mickaël De Backer (UCB, BE)\nHierarchical composite endpoints: more nuance, more insight and … more confusion?\nx\n\n\n2\nLukas Aguirre Dávila (alternate SAWP member, PEI, DE)\nHierarchical composite endpoints – time to untie the not’s?\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-7-keeping-it-real-or-losing-control-adventures-in-target-trial-emulation",
    "href": "data/2025/slides.html#session-7-keeping-it-real-or-losing-control-adventures-in-target-trial-emulation",
    "title": "Recordings",
    "section": "Session 7: Keeping it Real or Losing Control? Adventures in Target Trial Emulation",
    "text": "Session 7: Keeping it Real or Losing Control? Adventures in Target Trial Emulation\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nOlaf Klungel (MWP member, University of Utrecht, NL)\nBridging the Target Trial Emulation Framework and the Estimand Framework\nx\n\n\n2\nRima Izem (Novartis, CH)\nTarget Trial Emulation meets clinical trial design: two case studies\nx\n\n\n3\nAngelika Geroldinger (AGES, AT)\nFrom a regulatory perspective: what can we gain from TTE?\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-8-the-added-value-of-bayesian-methods-for-pivotal-clinical-trials-just-a-communication-issue",
    "href": "data/2025/slides.html#session-8-the-added-value-of-bayesian-methods-for-pivotal-clinical-trials-just-a-communication-issue",
    "title": "Recordings",
    "section": "Session 8: The Added Value of Bayesian Methods for Pivotal Clinical Trials – Just a Communication Issue?",
    "text": "Session 8: The Added Value of Bayesian Methods for Pivotal Clinical Trials – Just a Communication Issue?\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nKatharina Hees and Florian Krach (PEI, DE)\nBayesian approaches in clinical trials: a discussion on regulatory expectations\nx\n\n\n2\nNicky Best (GSK, UK)\nCommunicating the value of Bayesian approaches in clinical trials: is it just a prior issue?\nx"
  },
  {
    "objectID": "data/2025/slides.html#session-9-how-to-deal-with-assumptions-in-drug-development-what-insights-can-we-gain-from-ich-m15",
    "href": "data/2025/slides.html#session-9-how-to-deal-with-assumptions-in-drug-development-what-insights-can-we-gain-from-ich-m15",
    "title": "Recordings",
    "section": "Session 9: How to Deal with Assumptions in Drug Development? What Insights Can We Gain from ICH M15?",
    "text": "Session 9: How to Deal with Assumptions in Drug Development? What Insights Can We Gain from ICH M15?\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nFlora Musuamba Tshinanu (SAWP & MWP member, University of Namur, BE)\nFrom risk assessment to optimal regulatory decision: first having the question right\nx\n\n\n2\nOliver Sailer (Boehringer Ingelheim, DE)\nBridging disciplines with ICH M15: a case study on assumption testing for pharmacometric-enhanced Bayesian borrowing\nx\n\n\n3\nTobias Mielke (J&J, DE)\nICH-M15 to support credibility assessment for Bayesian modelling\nx"
  },
  {
    "objectID": "data/2025/slides.html#posters",
    "href": "data/2025/slides.html#posters",
    "title": "Recordings",
    "section": "Posters",
    "text": "Posters\n\n\n\n\n\n\n\n\n\n\n\nTalk\nSpeaker and affiliation\nTalk title\nDownload(if available)\n\n\n\n\n1\nSanne Roels, Alex Ocampo, Kelly Van Lancker (EFSPI Working Group Causal Inference SIG)\nCausal Inference Special Interest Group\n\n\n\n2\nBeate Presser, Christian Schmid, Jens Lamerz, Kevin Lief, Martin Motava (EFSPI Working Group CMC Statistical Network EU SIG)\nIntroduction to CMC statistical network Europe and areas for priority\nx\n\n\n3\nJonas Häggström (EFSPI/EFPIA EIWG with phuse sub-team)\nEFSPI Scientific & Training Academy – Past and Present\n\n\n\n4\nArmin Schüler, David Wright, Amel Besseghir, Khadija Rantell, Andreas Sashegyi, Katarina Hedman, George Kordzakhia, Mike Colopy, Liangcai Zhang (EFSPI statistical method leaders)\nEstimands in safety analytics\nx\n\n\n5\nMouna Akacha, Kaspar Rufibach (EFSPI statistical methodology leaders)\nStatistical methodology leaders in drug development, an EFSPI group\nx\n\n\n6\nFrank Pétavy, Eftychia Eirini Psarelli, Marie Annie Orre (HMA-EMA Network)\nClinical study data submission in Europe: An EMA-CHMP proof-of-concept pilot\nx\n\n\n7\nOliver Sailer, Monika Jelizarow (HTA SIG)\nHistorical Data: A PSI/EFSPI Special Interest Group\nx\n\n\n8\nMaximo Carreras, Chrissie Fletcher (HTA SIG)\nAdaptive Clinical Trials – what are the challenges and opportunities from an HTA perspective?\nx\n\n\n9\nBirte Geusens, Rachid Massaad, Anders Gorst-Rasmussen, Fred Sorenson, Shahrul Mt-Isa (HTA SIG)\nCharacterizing the effect of treatment using hierarchical composite endpoints – risks and benefits of win statistics and beyond in the HTA context\nx\n\n\n10\nKatrin Kupas, Min-Hua Jen, Orlando Dohring, Rima Izem (HTA SIG / RWE SIG)\nTarget trial emulation and incorporation of observational data into clinical trials from an HTA perspective\nx\n\n\n11\nAsh Bullement, Orlando Dohring, Peter Pemberton-Ross, Grammati Sarri, Katrin Kupas (HTA SIG)\nFrom trials to target populations: extending and extrapolating evidence for HTA decision-making\nx\n\n\n12\nLada Mitchell, Cornelia Dunger-Baldauf, Jenny Devenport, Yulia Dyachkova (Launch & Lifecycle SIG)\nUpdates from the Launch & Lifecycle SIG\nx\n\n\n13\nAudrey Yeo, Daniel Sabanés Bové, Alessandro Gasparini, Nils Penard (openstatsware / Software Engineering SIG)\nopenstatsguide: checklist for good statistical software packages\nx\n\n\n14\nJosephine Wolfram, Rima Izem, Elizabeth Merrall, Helen Broadhurst (Real World Data SIG)\nWelcome to the Real World Data SIG!\n\n\n\n15\nChristoph Gerlinger (Regulatory SIG)\nEFSPI/PSI regulatory European Special Interest Group\nx\n\n\n16\nGiles Partington, Maeva Dupuis, Aysun Cetinyurek Yavuz (Small populations SIG)\nThe PSI/EFSPI small population Special Interest Group\nx\n\n\n17\nBjoern Bornkamp, Kostas Sechidis, David Svensson, Ashwini Venkatasubramaniam (Treatment Effect Heterogeneity SIG)\nData-driven evaluation of treatment effect heterogeneity\nx"
  },
  {
    "objectID": "testimonials2024.html",
    "href": "testimonials2024.html",
    "title": "Linkedin posts reflecting on 2024 workshop",
    "section": "",
    "text": "To get an idea about the special spirit of the workshop we link a few linkedin posts reflecting on the 2024 issue.\n\n\n\n\n\nPoster\nTopic\nLink to post\n\n\n\n\nEFSPI\nSession 1: Fast to market\nlink\n\n\nEFSPI\nSession 2: Short topics\nlink\n\n\nEFSPI\nSession 3: China\nlink\n\n\nEFSPI\nSession 4: patient preference studies\nlink\n\n\nEFSPI\nSession 5: openstatsware\nlink\n\n\nEFSPI\nSession 6: Regulatory & HTA updates\nlink\n\n\nEFSPI\nSessions 7&8: HTA\nlink\n\n\nEFSPI\nWine tasting\nlink\n\n\nAnders Gorst-Rasmussen\nReflection on Session 1\nlink\n\n\nPeter Ahnesorg\nReflection on Session 1\nlink\n\n\nUrsula Becker\nReflection on Session 1\nlink\n\n\nAnna Wiksten\nReflecting on her talk as a patient and statistician in Session 4\nlink\n\n\nEgbert Biesheuvel\nReflection on entire workshop\nlink\n\n\n\n\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "2026.html",
    "href": "2026.html",
    "title": "2026 EFSPI regulatory statistics workshop",
    "section": "",
    "text": "The workshop will take place 19-20th August 2026 again at Biozentrum in beautiful Basel."
  },
  {
    "objectID": "2026.html#call-for-short-topics",
    "href": "2026.html#call-for-short-topics",
    "title": "2026 EFSPI regulatory statistics workshop",
    "section": "Call for short topics",
    "text": "Call for short topics\nLike previous years, it is possible to submit a short topic for discussion with a panel of regulators. Submit your proposal to the Chair, Vivian Lanius, by sending an e-mail to Vivian Lanius. Deadline for submissions is 21st July 2026."
  },
  {
    "objectID": "2026.html#registration",
    "href": "2026.html#registration",
    "title": "2026 EFSPI regulatory statistics workshop",
    "section": "Registration",
    "text": "Registration\nFor face-to-face attendance: 4th August 2026 EOB.\nRegistration platform will be turned off\n\nif we have reached maximum capacity of 300 face-to-face participants or\nfor the respective option after the deadline,\n\nwhatever happens first.\nFor virtual attendance: 17th August 2026 EOB."
  },
  {
    "objectID": "past_scicom.html",
    "href": "past_scicom.html",
    "title": "Past workshops: analysis of registrations and feedback (for restricted audience only)",
    "section": "",
    "text": "Analyses of registrations and feedbacks\n\n\n\n\n\nYear\nProgram\nSlidedecks\nFeedbacks\nRegistrations\n\n\n\n\n2016\nX\nX\n\n\n\n\n2017\nX\nX\n\n\n\n\n2018\nX\nX\n\n\n\n\n2019\nX\nX\nX\n\n\n\n2020\nX\nX\nX\n\n\n\n2021\nX\nX\nX\nX\n\n\n2022\nX\nX\nX\nX\n\n\n2023\nX\nX\nX\nX\n\n\n2024\nX\nX\n\nX\n\n\n2025\nX\nX\n\nX\n\n\n2026\nX\nX\n\nX"
  },
  {
    "objectID": "scicom.html",
    "href": "scicom.html",
    "title": "Scientific Committee",
    "section": "",
    "text": "How to get on the scientific committee\nPrinciples for joining the Scientific Committee have been outlined by EFSPI workshop leadership in this slidedeck.\n\n\nMembers\n\n2025202420232022\n\n\nIn 2025 the members of the scientific committee are (for regulators countries in parentheses):\n\n\n\n\n\n\n\n\n\n\n\n\nFirst\nLast\nGender\nType\nAffiliation\n\n\n\n\nJenny\nDevenport\nf\nIndustry\nRoche\n\n\nJulie\nJones\nf\nIndustry\nNovartis\n\n\nVivian\nLanius\nf\nIndustry\nUCB\n\n\nHelle\nLynggaard\nf\nIndustry\nNovo Nordisk\n\n\nEgbert\nBiesheuvel\nm\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nm\nIndustry\nRoche\n\n\nKaspar\nRufibach\nm\nIndustry\nMerck KGaA\n\n\nEmmanuel\nZuber\nm\nIndustry\nNovartis\n\n\nElina\nAsikanius\nf\nRegulator\nFIMEA (Finland)\n\n\nClaudia\nDallinger\nf\nIndustry\nBoehringer-Ingelheim\n\n\nBergrun\nMagnusdottir\nf\nRegulator\nIcelandic Medicines Agency (Iceland)\n\n\nHeidi\nMestl\nf\nRegulator\nLegemiddelverket (Norway)\n\n\nAnouk\nNeven\nf\nRegulator\nLuxembourg Institute of Health\n\n\nKhadija\nRantell\nf\nRegulator\nMHRA (UK)\n\n\nAnja\nSchiel\nf\nHTA/Regulator\nLegemiddelverket\n\n\nLukas\nAguirre Davila\nm\nRegulator\nPaul-Ehrlich Institute (Germany)\n\n\nAndreas\nBrandt\nm\nRegulator\nBfARM (Germany)\n\n\nRob\nHemmings\nm\nConsultant\nConsilium\n\n\nBenjamin\nHofner\nm\nRegulator\nPaul-Ehrlich Institute (Germany)\n\n\nSeamus\nKent\nm\nHTA/Regulator\nErasmus School of Health Policy & Management\n\n\nFlorian\nKlinglmueller\nm\nRegulator\nAGES (Austria)\n\n\nPierre\nMancini\nm\nIndustry\nSanofi\n\n\nKit\nRoes\nm\nRegulator\nCBG (Netherlands)\n\n\nRafael\nSauter\nm\nRegulator\nSwissmedic\n\n\nPatrick\nSchloemer\nm\nIndustry\nBayer\n\n\nAndrew\nThomson\nm\nRegulator\nEMA\n\n\nFredrik\nÖhrn\nm\nIndustry\nJ&J\n\n\n\n\n\n\n\nIn 2024 the members of the scientific committee were (for regulators countries in parentheses):\n\n\n\n\n\n\n\n\n\n\n\n\nFirst\nLast\nGender\nType\nAffiliation\n\n\n\n\nJenny\nDevenport\nf\nIndustry\nRoche\n\n\nJulie\nJones\nf\nIndustry\nNovartis\n\n\nHelle\nLynggaard\nf\nIndustry\nNovo Nordisk\n\n\nEgbert\nBiesheuvel\nm\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nm\nIndustry\nRoche\n\n\nKaspar\nRufibach\nm\nIndustry\nRoche\n\n\nEmmanuel\nZuber\nm\nIndustry\nNovartis\n\n\nElina\nAsikanius\nf\nRegulator\nFIMEA (Finland)\n\n\nCorine\nBaayen\nf\nIndustry\nFerring\n\n\nVivian\nLanius\nf\nIndustry\nBayer\n\n\nBergrún\nMagnúsdóttir\nf\nRegulator\nIcelandic Medicines Agency (Iceland)\n\n\nHeidi\nMestl\nf\nRegulator\nLegemiddelverket (Norway)\n\n\nEftychia Eirini\nPsarelli\nf\nRegulator\nEMA\n\n\nKhadija\nRantell\nf\nRegulator\nMHRA (UK)\n\n\nGiulia\nZigon\nf\nIndustry\nGSK\n\n\nLukas\nAguirre Davila\nm\nRegulator\nPaul-Ehrlich Institute (Germany)\n\n\nAndreas\nBrandt\nm\nRegulator\nBfARM (Germany)\n\n\nAnders\nGorst-Rasmussen\nm\nIndustry\nNovo Nordisk\n\n\nBenjamin\nHofner\nm\nRegulator\nPaul-Ehrlich Institute (Germany)\n\n\nWolfgang\nJacquet\nm\nRegulator\nFAMHP (Belgium)\n\n\nFlorian\nKlinglmueller\nm\nRegulator\nAGES (Austria)\n\n\nPierre\nMancini\nm\nIndustry\nSanofi\n\n\nKit\nRoes\nm\nRegulator\nCBG (Netherlands)\n\n\nDavid\nWright\nm\nIndustry\nAstraZeneca\n\n\nFredrik\nÖhrn\nm\nIndustry\nJ&J\n\n\n\n\n\nIn 2024 we also had a committee that contributed to the planning of HTA talks.\n\n\n\n\n\nFirst\nLast\nGender\nType\nAffiliation\n\n\n\n\nLilla\nDi Scala\nf\nIndustry\nJ&J\n\n\nKatrin\nKupas\nf\nIndustry\nBMS\n\n\nAntonia\nMorga\nf\nIndustry\nAstellas\n\n\nAnders\nGorst-Rasmussen\nm\nIndustry\nNovo Nordisk\n\n\nSandro\nGsteiger\nm\nIndustry\nRoche\n\n\nFrancois\nMaignen\nm\nHTA\nNICE UK\n\n\n\n\n\n\n\nIn 2023 the members of the scientific committee were (for regulators countries in parentheses):\n\n\n\n\n\n\n\n\n\n\n\n\nFirst\nLast\nGender\nType\nAffiliation\n\n\n\n\nElina\nAsikanius\nF\nRegulator\nFIMEA (Finland)\n\n\nEftychia-Eirini\nPsarelli\nF\nRegulator\nEMA\n\n\nKhadija\nRantell\nF\nRegulator\nMHRA (UK)\n\n\nLukas\nAguirre Dávila\nM\nRegulator\nPaul-Ehrlich Institute (Germany)\n\n\nAndreas\nBrandt\nM\nRegulator\nBfARM (Germany)\n\n\nLorenzo\nHess\nM\nRegulator\nSwissmedic (Switzerland)\n\n\nBenjamin\nHofner\nM\nRegulator\nPaul-Ehrlich Institute (Germany)\n\n\nWolfgang\nJacquet\nM\nRegulator\nFAMHP (Belgium)\n\n\nAndreas\nKirisits\nM\nRegulator\nAGES\n\n\nFlorian\nKlinglmueller\nM\nRegulator\nAGES (Austria)\n\n\nArmin\nKoch\nM\nRegulator\nEMA\n\n\nKit\nRoes\nM\nRegulator\nCBG (Netherlands)\n\n\nFerran\nTorres\nM\nRegulator\nAEMPS (Spain)\n\n\nCorine\nBaayen\nF\nIndustry\nLundbeck\n\n\nRandi\nGrøn\nF\nIndustry\nNovo Nordisk\n\n\nVivian\nLanius\nF\nIndustry\nBayer\n\n\nHelle\nLynggaard\nF\nIndustry\nNovo Nordisk\n\n\nGiulia\nZigon\nF\nIndustry\nGSK\n\n\nEgbert\nBisheuvel\nM\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nM\nIndustry\nRoche\n\n\nChristoph\nGerlinger\nM\nIndustry\nBayer\n\n\nFredrik\nÖhrn\nM\nIndustry\nJ&J\n\n\nKaspar\nRufibach\nM\nIndustry\nRoche\n\n\nDavid\nWright\nM\nIndustry\nAstraZeneca\n\n\nEmmanuel\nZuber\nM\nIndustry\nNovartis\n\n\nAnja\nSchiel\nF\nHTA/Regulator\nLegemiddelverket (Norway)\n\n\nMaignen\nFrancois\nM\nHTA\nNICE\n\n\n\n\n\n\n\nIn 2022 the members of the scientific committee were:\n\n\n\n\n\n\n\n\n\n\n\n\nFirst\nLast\nGender\nType\nAffiliation\n\n\n\n\nElina\nAsikanius\nf\nRegulator\nFinnish Medicines Agency\n\n\nEftychia Eirini\nPsarelli\nf\nRegulator\nEMA\n\n\nKhadija\nRantell\nf\nRegulator\nMHRA\n\n\nAnja\nSchiel\nf\nRegulator\nNorwegian Medicine Agency\n\n\nAndreas\nBrandt\nm\nRegulator\nBfArM\n\n\nLorenzo\nHess\nm\nRegulator\nSwissmedic\n\n\nArmin\nKoch\nm\nRegulator\nMedizinische Hochschule Hannover\n\n\nKit\nRoes\nm\nRegulator\nRadboud UMC\n\n\nRandi\nGrøn\nf\nIndustry\nNovo Nordisk\n\n\nHelle\nLynggaard\nf\nIndustry\nNovo Nordisk\n\n\nViktoriya\nStalbovskaya\nf\nIndustry\nMerus\n\n\nEgbert\nBiesheuvel\nm\nIndustry\nViatris\n\n\nHans Ulrich\nBurger\nm\nIndustry\nRoche\n\n\nChristoph\nGerlinger\nm\nIndustry\nBayer\n\n\nKaspar\nRufibach\nm\nIndustry\nRoche\n\n\nDavid\nWright\nm\nIndustry\nAstraZeneca\n\n\nEmmanuel\nZuber\nm\nIndustry\nNovartis\n\n\n\n\n\nSee also the program of 2022.\n\n\n\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "speaker.html",
    "href": "speaker.html",
    "title": "Frequently asked questions for speakers and panelists",
    "section": "",
    "text": "You have agreed to contribute to the 11th EFSPI regulatory statistics workshop. Many thanks for that!"
  },
  {
    "objectID": "speaker.html#for-participants",
    "href": "speaker.html#for-participants",
    "title": "Frequently asked questions for speakers and panelists",
    "section": "For participants",
    "text": "For participants\nThe registration fee is waived for participating students and members of regulatory agencies. When registering simply chose the virtual or face-to-face option but do not pay the registration fee."
  },
  {
    "objectID": "speaker.html#for-contributors",
    "href": "speaker.html#for-contributors",
    "title": "Frequently asked questions for speakers and panelists",
    "section": "For contributors",
    "text": "For contributors\nFor\n\ncontributing academics (incl. students),\nmembers of the Scientific Program Committee,\nsession chairs, presenters, and\ninvited panelists\n\nwe are able to offer the following benefits, depending on your affiliation:\n\n\n\n\n\n\n\n\n\n\n\n\nExpense\nStudents\nIndustry\nAcademic\nRegulatory\n\n\n\n\nRegistration fee\nwaived\nwaived\nwaived\nwaived\n\n\nTravel 2nd / economy class\n\n\nReimbursed\nReimbursed\n\n\nHotel accommodation\n\n\nReimbursed\nReimbursed\n\n\n\n\n\nHowever, if the registration fee is waived for you please still register using this form.\nPlease book all your travel yourself. For reimbursement please complete this form after the event and send it to Egbert Biesheuvel.\nRegistration fee is not waived for poster and short topic session presenters."
  },
  {
    "objectID": "dialin.html",
    "href": "dialin.html",
    "title": "Dialing-in instructions for contributors",
    "section": "",
    "text": "You have agreed to contribute to the EFSPI regulatory statistics workshop. Many thanks for that!"
  },
  {
    "objectID": "dialin.html#zoom",
    "href": "dialin.html#zoom",
    "title": "Dialing-in instructions for contributors",
    "section": "Zoom",
    "text": "Zoom\n\nAll of you have been set up as Zoom Panelist for both days. You should have received a personal email with your own personalized link to join the webinar. The email is from Laurence Guillier from the email address no-reply@zoom.us with subject line Webinar host invited you to be panelist for 9th EFSPI Regulatory Statistics Workshop_Day 1/2.\nPlease exclusively use the link in the above email and do not join as an attendee - otherwise you will not be in the practice session prior to the TC.\nWe would appreciate if you could dial in about 20min early into the practice session, for us to check that everything works. Attendees can dial in but will not be in the webinar before we let them in. You will not need to log out from this session and can just stay in.\nOnly panelists will have the option to turn on their camera and microphon. Attendees can only speak when we unmute them (which we do not plan for, we will invite them to ask questions through the chat).\nStatus of registrations: Find this here. We have 771 registrations from 30 countries as of now, with 320 face-to-face. 58 colleagues from regulatory agencies registered so far.\nThe current version of the program is Program is not available yet."
  },
  {
    "objectID": "dialin.html#face-to-face-attendance",
    "href": "dialin.html#face-to-face-attendance",
    "title": "Dialing-in instructions for contributors",
    "section": "Face-to-face attendance",
    "text": "Face-to-face attendance\n\nVenue: The event takes place in the Biozentrum in Basel (directions), in the Maurice Müller Lecture hall in the basement.\nWLAN in the Biozentrum: Connect to Unibas visitor. It will ask for your mobile phone number for confirmation.\nUpon arrival we ask you to register at the conference desk and to pick up your badge."
  },
  {
    "objectID": "chat.html",
    "href": "chat.html",
    "title": "Session Q&A Zoom chat observers",
    "section": "",
    "text": "Introduction\nOn this page we summarize instructions for industry session chairs and chat observers with respect to the inclusion of questions from the virtual attendees for each session.\n\n\nChat observer\nYou have registered for face-to-face participation to the EFSPI regulatory statistics workshop as a Roche or Novartis colleague with statistics background.\nThe local organizing committee members thanks you for agreeing to be a chat observer! The ask for this task would be:\n\nIdentify your industry session chair from the Program is not available yet and make yourself known to her/him ahead of the session.\nSit in the front row, as close as possible to the industry session chair.\nBring your laptop, dial in to the zoom TC.\nMonitor the Q&A part of zoom (that is where virtual attendees are supposed to ask questions) and\n\ncontinuously collate questions into themes,\nprioritize them,\nidentify how they relate to the ongoing discussion in the room,\nwave at the industry session chair to inform her/him that there are questions from the chat,\nto be ready to share them when appropriate.\n\nUpon being invited to by the industry session chair share them with the room.\n\n\n\nIndustry session chair\nAs an industry session chair co-moderating the session and the discussion afterwards, we invite you to frequently ask the chat observer for further questions from the online audience.\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "submission.html",
    "href": "submission.html",
    "title": "Frequently asked questions for submissions of contributions",
    "section": "",
    "text": "Primary goal of the EFSPI regulatory statistics workshop\nSee here.\n\n\nTalks\nThe scientific committee, with equal representation of industry and European regulatory members, regularly meets and puts together a program structured in several sessions. In order to have a focused and fit-for-purpose program talks are by invitation only. There is no option to submit talks for presentation in one of the sessions.\nWonder how you can get involved with the scientific committee? See here.\n\n\nShort topics\nThe short topics session is a hallmark of each year’s workshop. Anyone can submit proposals for discussion until 21st July 2026 to Vivian Lanius. Accepted proposals can be presented in five minutes using two slides to the audience, with the intention to ask one or more clear questions to a panel of regulators. They will then comment on these questions. For past topics that were discussed in this session see here.\nFor instructions on how to present in the short topic session if your questions were accepted see here.\n\n\nPosters\nThe primary purpose of the poster session is to give EFSPI / PSI eSIGs the opportunity to present their progress. As for talks, there is no option to submit posters other than from said eSIGs.\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  },
  {
    "objectID": "chairs.html",
    "href": "chairs.html",
    "title": "Workshop chairs",
    "section": "",
    "text": "Year\nchair\nCompany\n\n\n\n\n2026\nVivian Lanius\nUCB\n\n\n2025\nVivian Lanius\nUCB\n\n\n2024\nHelle Lynggaard\nNovo Nordisk\n\n\n2023\nHelle Lynggaard\nNovo Nordisk\n\n\n2022\nKaspar Rufibach\nRoche\n\n\n2021\nKaspar Rufibach\nRoche\n\n\n2020\nKaspar Rufibach\nRoche\n\n\n2019\nUli Burger\nRoche\n\n\n2018\nUli Burger\nRoche\n\n\n2017\nUli Burger\nRoche\n\n\n2016\nUli Burger\nRoche\n\n\n\n\n\n\nQuestions?\nFor feedback and questions send an email to Vivian Lanius."
  }
]